CD163 and COVID-19: Moreover, GSK3 inhibition increased the expression of the gene sets that define pathogenic pro-fibrotic macrophage subsets in severe COVID-19 ([Group 3 or SPP1+, GSE145926] [Liao et al., 2020], MoAM3 [GSE155249] [Grant et al., 2021] or CD163+/LGMN+ MØ [EGAS00001005634] [Wendisch et al., 2021]) (Figure 1I).